Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
about
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin.Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair.
P2860
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Clinical Application of Poly
@nl
Clinical Application of Poly(A ...... h-Grade Serous Ovarian Cancer.
@ast
Clinical Application of Poly(A ...... h-Grade Serous Ovarian Cancer.
@en
type
label
Clinical Application of Poly
@nl
Clinical Application of Poly(A ...... h-Grade Serous Ovarian Cancer.
@ast
Clinical Application of Poly(A ...... h-Grade Serous Ovarian Cancer.
@en
prefLabel
Clinical Application of Poly
@nl
Clinical Application of Poly(A ...... h-Grade Serous Ovarian Cancer.
@ast
Clinical Application of Poly(A ...... h-Grade Serous Ovarian Cancer.
@en
P2860
P1433
P1476
Clinical Application of Poly(A ...... gh-Grade Serous Ovarian Cancer
@en
P2093
Richard D Kennedy
P2860
P304
P356
10.1634/THEONCOLOGIST.2015-0438
P577
2016-03-28T00:00:00Z